In a single-blind, randomised, parallel-group study comparing the efficacy and tolerability of dothicpin (50-150 mg per day) and imipraniine (50-150 mg per day) for6weeks, involving 60 adult patientswith depression, it was observed that dothiepin was comparable to imipramine in terms of efficacy as assessed by Hamilton Rating Scale for depress ion, global scale for severty of illness and clinifian's overall assessment of efficacy. Dothiepin was found to have a significantly earlier onset of anxiolytic action compared to imipramine. Dothiepin was well tolerated.
Dothiepin (Prothiadenn) is a tricyclic antidepressant which was first synthesized by Rajsner and protiva in 1962. It is a thio analogue of anv'triptyline. Early clinical work on dothiepin suggested that the drug has both antidepressant and anxiolytic properties (Rydzynski, 1966) . In subsequent clinical studies, the drug has been shown to be an effective antidepressant with associated anx'olytic action in depression fLipsedge et al., 1971; Johnson et al., 1973 and Sharma, 1981) . Dothiepin has been shown to be well tolerated in clinical studies (Goldstein and Claghorn, 1980) . The present study was planned to evaluate the efficacy ard safety of dothiepin in comparison to imipramine, a commonly used tricyclic antidepressant, in patients suffering from depression.
trial, an immediate danger of Suicide and need for electroconvulsive therapy for the present episode.
The patients admitted into the trial were randomly allocated to receive either im'pratnine or dothiepin-The following was the dosage adm'nistration of trial therapy : Day 1 to Day 3 : 50 mg as a single dose at night; Day 4 to Day 14 : 75 mg as a single dose at night; Day 15 (week 3) to Day 42 (week 6) : If response was considered inadequate to single dose of 75 mg daily, the dose of the drug was increased gradually, as per the clinician's judgement, upto 150 mg per day. The dose in excess of 75 mg was given in divided doses.
Clinical assessment of drug efficacy was based or the following parameters; these being carried out by an independent psychiatrist who was not aware of the drug received by the patient : (1) Severity of depressive illness using Hamilton Rating Scale for depression (Hamilton, 1960) prior to and at weekly intervals after commencing drug therapy. (2) Global scale for severity of illnessusing the snb : ective judgement of the clinician as 0-not ill, 1-mild, 2-moderate, 3-severe and 4-very severe. This was recorded prior to initiation of drug therapy and thereafter at weekly intervals. (3) Clinician's overall assessment of effiicacy-recorded at the end of 6 weeks of drug therapy on a 0-6 scale as 0-symptoms cleared, 1-marked improvement, 2-moderate improvement, 3-slight improvement, 4-no change, 5-worse and 6-withdrawn. Assessment of tolsrab'lity and safety was carried out u ; ing the following parameters : (I) Side-efFects -those observed bv the physician or volunteered by the patient were recorded and the severity graded as 1-mild, 2-moderate, or 3-severe. A checklist of symptoms was completed prior to initiation of drug therapy so as to rule ovt disease-related symptoms being reported as 'drug' side-effects. (2) Cardiovascular cxam'nat^-this included recording the supine and erect blood pressure and pulse rate prior to and at weekly iitervals during therapv. A 12-lead electrocardiogram was recorded before commencing drug therapy and after 3 and P weeks of therapy. (3) Laboratory investigations-routine friematological and biochemical investigations and Urnalysis were carried out before and after drug therapy.
Results
Sixty patients were enrolled in the study of whom 32 patients were randomised to receive dothiepin and 28 to receive iroipramine. Five patients in each group did not fullfill the protocol requirements and were excluded from the analysis. Five patients receiving dothiepin and 4 receiving imipraminc failed to attend the clinic regula r ly and therefore, their data were excluded for analysis of efficacy. Three patients receiving dothiepin and one receiving imipramire developed hypomanic/manic features such as elated mood, increased psychomotor activity, grand : ose delusio/i, distractab : lity and flight of ideas and hence could not continue their med'eation. It is know.a that tricyclic antidepressants nvay unmask mania in bipolar disorder (American Medical Association, 1986)-The data of these patients have not been included for efficacy assessments but have been included in safety evaluation. Thus the data for 19 patients in the dothiepin group and 18 in the imiprarnine group were analy- sed for efficacy ar.d 27 in the dothiepin and 23 in the imipramine groups for tolerability. The demographic details of the two treatment groups are presented in Table  1 . The groups were comparable except that patients in the imipramine group (mean age 45.8 years) were older compared to those in the dothiepin group (mean age 37.0 years'!. The dosage of the two drugs used in the study ranged from 50-150mg per day.
CLINICAL EFFICACY
Hamilton Rating Scale : The mean total Hamilton scores for dothiepin and imipranvn^ treated groups of patients before and during 6 weeks of drug therapy are depicted in Figure 1 . Both the drugs produced significant reduction in the mean total Hamilton scores at each assessment period during therapy (weeks 1-6) compared to the baseline scores (p<0.01, Wdcoxon matched-pairs, sigiedranks test). There was no significant difference between the two groups in terms of reduction in total Hamilton scores (p>0.05, Mann-Whitney test).
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The anxiety scores were analysed separately and are graphically presented in Figure 2 . It was observed that dothiepin resulted in significant reduction in anxiety scores from week 1 to week 6 of therapy; with imipramine, a significant reduction was observed only from week 3 of therapy (p<0.05, Wilcoxon matched-pairs, signed-rank test). The difference between the two drugs was -ignificant in favour of dothiepin at week 1 of therapy suggesting an earlier onset of anxiolytic effect (p<0.05, MannWhitncy test).
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Olobal Scale for Severity of Illness : Both dothiepin and imipramine produced significant reduction in severity of illness from week ] of therapy ( Table  2 ). The patients in the dothiepin group had a significantly greater severity score prior to comtnencirg drug therapy than those in the imipramine group (p<0.05, Mann-Whitney test). Therefore, the percentage from pre-therapy was calculated and used for comparison between the two groups. The difference between the two drugs did not reach a level of statistical significance in this regard (p>0.05, Mann-Whitney test).
Clinician's Overall Assessment of Efficacy : All 19 patients (100%) in the dothiepin group and 16 patients (88.9 %) in the imipramine group had improved at the sixth week of assessment, as rated by the clinician (Table 3) . The difference between the two groups was not statistically significant (p>0.05, Mann-Whitney test).
TOLERABILITY
Side-tfftcts : Oulf of 27 evaluable patients receiving dothiepin, J4 reported side-effects, while 12 of the 23 evaluable patients receiving imipramine reported side-effects (p>0.05, X 2 test). With dothiepin, 14 patients complained of a total of 21 side-effects and with imipramine, 12 patients complained of a total of 25 side-effects. The side-effects reported were typical of those reported with tricyclic antidepressants (Table 4 ). The mean composite severity score (-[-S.E.M.) was 0.93±0.2 for dothiepin and 1.34±0.39 for imipramine. Total number of sideeffects and severity of side-effects was higher with imipramine than with dothiepin; however, the difference between the two drugs did not reach a level of statistical significance (p<0.05, MannWhitney test).
Cardiovascular Examination :
The drugs under study did not affect the pulse rate, supine and erect blood pressure to a clinically significant level, except for one patient receiving imipramine who experienced postural hypotension and sudden fall during end of week 1 of therapy. Imipramine therapy was continued in this patient for six weeks. No EGG changes were observed in either the dothiepin or imipramine groups.
Laboratory Inoetigations i Haematological and biochemical investigations and urinalysis showed no clinically significant changes.
Discussion
The results of the study corroborated the findings of Simetal. (1975) and Eilenberg (1980) who have also observed that dothiepin is comparable in efficacy to imipramine. In this study, dothiepin was found to have an earlier onset of anxiolytic action compared to imipramine. The earlier onset of anxiolytic action of dothiepin has also been reported by Sharma (1981) and Vencovsky et al. (1964) . This feature of dothiepin will be of benefici- . ±0.05* ±0.14** ±0.13** ±0.12** ±0.14** ±0.14** ±0.13** Imipramine 1.7 1.1 0.9 0.8 0.4 0.4 0.5 (n = 18) ±0.16* ±0.14** ±0.14** ±0.20** ±0.14** ±0.17** ±0.17** *p<0.05, (Mann-Whitney test) **p<0.05 (Wilcoxon matched-pairs, signed-rank test). Table 3 . Clinicians overall assessment of efficacy al value since anxiety is frequently associated with depression and early relief of anxiety is likely to aid patient compliance. Dothiepin has been reported to have lower incidence of side-effects (Sim et al., 1975 and Eilenberg, 1980) and lesser severity of side-effects compared to imipramine (Sim et al., 1975) . In this study the frequency and severity of side-effects were less with dothiepin compared to im'pramine but this difference did not reach a level of statistical significance.
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